IPAM
Ipamorelin
A synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It binds the growth hormone secretagogue receptor type 1a, the same receptor the endogenous peptide ghrelin acts on, and is described in the literature as selective for that receptor rather than acting across the wider set of pituitary secretagogue targets.
Ipamorelin has 2 registered human studies on ClinicalTrials.gov, reaching phase 2, covering 437 planned or enrolled participants across the 2 studies that published a figure. No FDA-approved product contains Ipamorelin. 18 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Ipamorelin; the registry search is fuzzy, so every match is re-checked. None of this says whether Ipamorelin works or is safe.
FDA status
Research only
Human studies
2
Furthest phase
Phase 2
Papers, 10 yr
18
Readership
6,559
monthly average, Feb–Jun 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
Phase 1 or 2 only
2
Registered human studies
Phase 2
Furthest phase reached
437
Planned or enrolled participants, across 2 studies that published a figure
None
No FDA-approved product contains it
3 loose registry matches were checked and 2 confirmed — 1 named something else and were discarded. We count a study only when Ipamorelin is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Ipamorelin is, and what it has been studied for
Ipamorelin is classified by ChEMBL as a protein, and appears in trial registrations under NNC 26-0161 and NNC-26-0161. Its FDA substance identifier is Y9M3S784Z6.
Across 2 registered trials, it has been studied in Ileus and Gastrointestinal Dysmotility. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Helsinn Therapeutics (U.S.), Inc. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Ipamorelin reached Phase 2 across 2 registered trials.
No FDA-approved product contains Ipamorelin. A compound can stop at any rung for commercial reasons as easily as scientific ones, and the registry does not record which.
Is anyone studying Ipamorelin?
Papers published each year that name Ipamorelin in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 2 | 0 | Yes |
| 2018 | 4 | 0 | Yes |
| 2019 | 1 | 0 | Yes |
| 2020 | 2 | 0 | Yes |
| 2021 | 0 | 0 | Yes |
| 2022 | 0 | 0 | Yes |
| 2023 | 0 | 0 | Yes |
| 2024 | 2 | 0 | Yes |
| 2025 | 0 | 0 | Yes |
| 2026 | 8 | 0 | No |
18 papers between 2017 and 2026. A paper counts when “Ipamorelin” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Ipamorelin
18 indexed papers name Ipamorelin in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Ipamorelin, the first selective growth hormone secretagogue
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
- Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males
- Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
- The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism
- Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats
Collected 2026-08-02from PubMed, phrase-matched on “Ipamorelin” in title and abstract. Run the same search.
About Ipamorelin
A synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It binds the growth hormone secretagogue receptor type 1a, the same receptor the endogenous peptide ghrelin acts on, and is described in the literature as selective for that receptor rather than acting across the wider set of pituitary secretagogue targets.
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.